麦科医药-B：MT1002试验完成首例入组
2026-07-05 05:25:00
据中国证券报报道，7月3日，麦科医药-B（02335.HK）公告称，其自主研发的急性缺血性卒中管线MT1002的Ib/II期临床试验完成首例患者入组。该试验为多中心、分两部分设计：第一部分评估安全性及药代动力学特征；第二部分在更大规模患者中通过随机、标准治疗对照进一步评价。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
